Agenus reports 48% three-year survival with BOT+BAL in ovarian cancer

Agenus Inc. announced three-year follow-up results from the ovarian cancer cohort of its Phase 1b C-800-01 trial, evaluating botensilimab (BOT) in combination with balstilimab (BAL). The study showed an estimated three-year survival rate of 48% in recurrent ovarian cancer.